Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial

Steven Nash, Sherif Aboseif, Peter Gilling, Matthew B Gretzer, Harvey Samowitz, Marc Rose, Joel Slutsky, Steven Siegel, Le Mai Tu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: This paper presents 18-month follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The trial evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI). Methods: The clinical study involved 11 clinical sites and enrolled 160 subjects. A total of 124 subjects met study criteria and 123 underwent ProACT implantation from July 2005 through June 2007, of whom 98 completed 18-month follow-up. Endpoints included 24-h pad weight, Incontinence Quality of Life Questionnaire (I-QOL), UCLA Prostate Cancer Index-Urinary Function (PCI-UF), residual volume, and device or procedure-related adverse events (AEs). Results: The mean surgical time was 32 min. Statistically significant improvements during follow-up were observed in 24-h pad weight, for which the cohort mean pre-implant urine loss was 399 g, which was reduced at 18 months to 160 g (P < 0.001). Reductions in pad weight were observed across all levels of pre-implant SUI severity. Significant improvements were also seen in quality of life as measured by the I-QOL (P < 0.001) as well as measures of urinary function and pad count. One procedure-related serious adverse event (SAE), retention, was reported among the 124 subjects; the SAE was resolved without clinical meaningful sequalae. Conclusions: These results demonstrate the safety and efficacy of this newly FDA-approved therapy, showing significant improvements in objective and subjective measures of SUI in mild, moderate, and severely incontinent male patients. The duration of the implant procedure is short, and complications are mild and easily resolvable.

Original languageEnglish (US)
JournalNeurourology and Urodynamics
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Prostatectomy
Stress Urinary Incontinence
Quality of Life
Weights and Measures
Incontinence Pads
Safety
Residual Volume
Therapeutics
Operative Time
Prostatic Neoplasms
Urine
Equipment and Supplies
Surveys and Questionnaires

Keywords

  • incontinence
  • prosthesis
  • quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Urology

Cite this

Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence : The ProACT™ pivotal trial. / Nash, Steven; Aboseif, Sherif; Gilling, Peter; Gretzer, Matthew B; Samowitz, Harvey; Rose, Marc; Slutsky, Joel; Siegel, Steven; Tu, Le Mai.

In: Neurourology and Urodynamics, 01.01.2018.

Research output: Contribution to journalArticle

Nash, Steven ; Aboseif, Sherif ; Gilling, Peter ; Gretzer, Matthew B ; Samowitz, Harvey ; Rose, Marc ; Slutsky, Joel ; Siegel, Steven ; Tu, Le Mai. / Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence : The ProACT™ pivotal trial. In: Neurourology and Urodynamics. 2018.
@article{91cc11fcd7e447bd813985a76b637b59,
title = "Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence: The ProACT™ pivotal trial",
abstract = "Aims: This paper presents 18-month follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The trial evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI). Methods: The clinical study involved 11 clinical sites and enrolled 160 subjects. A total of 124 subjects met study criteria and 123 underwent ProACT implantation from July 2005 through June 2007, of whom 98 completed 18-month follow-up. Endpoints included 24-h pad weight, Incontinence Quality of Life Questionnaire (I-QOL), UCLA Prostate Cancer Index-Urinary Function (PCI-UF), residual volume, and device or procedure-related adverse events (AEs). Results: The mean surgical time was 32 min. Statistically significant improvements during follow-up were observed in 24-h pad weight, for which the cohort mean pre-implant urine loss was 399 g, which was reduced at 18 months to 160 g (P < 0.001). Reductions in pad weight were observed across all levels of pre-implant SUI severity. Significant improvements were also seen in quality of life as measured by the I-QOL (P < 0.001) as well as measures of urinary function and pad count. One procedure-related serious adverse event (SAE), retention, was reported among the 124 subjects; the SAE was resolved without clinical meaningful sequalae. Conclusions: These results demonstrate the safety and efficacy of this newly FDA-approved therapy, showing significant improvements in objective and subjective measures of SUI in mild, moderate, and severely incontinent male patients. The duration of the implant procedure is short, and complications are mild and easily resolvable.",
keywords = "incontinence, prosthesis, quality of life",
author = "Steven Nash and Sherif Aboseif and Peter Gilling and Gretzer, {Matthew B} and Harvey Samowitz and Marc Rose and Joel Slutsky and Steven Siegel and Tu, {Le Mai}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/nau.23802",
language = "English (US)",
journal = "Neurourology and Urodynamics",
issn = "0733-2467",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Treatment with an adjustable long-term implant for post-prostatectomy stress incontinence

T2 - The ProACT™ pivotal trial

AU - Nash, Steven

AU - Aboseif, Sherif

AU - Gilling, Peter

AU - Gretzer, Matthew B

AU - Samowitz, Harvey

AU - Rose, Marc

AU - Slutsky, Joel

AU - Siegel, Steven

AU - Tu, Le Mai

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Aims: This paper presents 18-month follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The trial evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI). Methods: The clinical study involved 11 clinical sites and enrolled 160 subjects. A total of 124 subjects met study criteria and 123 underwent ProACT implantation from July 2005 through June 2007, of whom 98 completed 18-month follow-up. Endpoints included 24-h pad weight, Incontinence Quality of Life Questionnaire (I-QOL), UCLA Prostate Cancer Index-Urinary Function (PCI-UF), residual volume, and device or procedure-related adverse events (AEs). Results: The mean surgical time was 32 min. Statistically significant improvements during follow-up were observed in 24-h pad weight, for which the cohort mean pre-implant urine loss was 399 g, which was reduced at 18 months to 160 g (P < 0.001). Reductions in pad weight were observed across all levels of pre-implant SUI severity. Significant improvements were also seen in quality of life as measured by the I-QOL (P < 0.001) as well as measures of urinary function and pad count. One procedure-related serious adverse event (SAE), retention, was reported among the 124 subjects; the SAE was resolved without clinical meaningful sequalae. Conclusions: These results demonstrate the safety and efficacy of this newly FDA-approved therapy, showing significant improvements in objective and subjective measures of SUI in mild, moderate, and severely incontinent male patients. The duration of the implant procedure is short, and complications are mild and easily resolvable.

AB - Aims: This paper presents 18-month follow-up results for patients enrolled in a pivotal study conducted to support an FDA premarket approval application (PMAA). The trial evaluated the safety and efficacy of the ProACT Adjustable Continence Therapy for the treatment of post-prostatectomy stress urinary incontinence (SUI). Methods: The clinical study involved 11 clinical sites and enrolled 160 subjects. A total of 124 subjects met study criteria and 123 underwent ProACT implantation from July 2005 through June 2007, of whom 98 completed 18-month follow-up. Endpoints included 24-h pad weight, Incontinence Quality of Life Questionnaire (I-QOL), UCLA Prostate Cancer Index-Urinary Function (PCI-UF), residual volume, and device or procedure-related adverse events (AEs). Results: The mean surgical time was 32 min. Statistically significant improvements during follow-up were observed in 24-h pad weight, for which the cohort mean pre-implant urine loss was 399 g, which was reduced at 18 months to 160 g (P < 0.001). Reductions in pad weight were observed across all levels of pre-implant SUI severity. Significant improvements were also seen in quality of life as measured by the I-QOL (P < 0.001) as well as measures of urinary function and pad count. One procedure-related serious adverse event (SAE), retention, was reported among the 124 subjects; the SAE was resolved without clinical meaningful sequalae. Conclusions: These results demonstrate the safety and efficacy of this newly FDA-approved therapy, showing significant improvements in objective and subjective measures of SUI in mild, moderate, and severely incontinent male patients. The duration of the implant procedure is short, and complications are mild and easily resolvable.

KW - incontinence

KW - prosthesis

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85052975085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052975085&partnerID=8YFLogxK

U2 - 10.1002/nau.23802

DO - 10.1002/nau.23802

M3 - Article

C2 - 30178536

AN - SCOPUS:85052975085

JO - Neurourology and Urodynamics

JF - Neurourology and Urodynamics

SN - 0733-2467

ER -